Axonics® reports preliminary fourth quarter and fiscal year 2021 revenue

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported preliminary unaudited net revenue for the three months and fiscal year ended december 31, 2021. 4q21 total company net revenue is expected to be in the range of $52.9 to $53.3 million, an increase of 53% compared to $34.8 million in the prior year period. 4q21 sacral neuromodula
AXNX Ratings Summary
AXNX Quant Ranking